−8.79MXN
−2.57 BMXN
6.78 BMXN
286.56 M
About AMICUS THERAPEUTICS INC
Sector
CEO
Bradley Lewis Campbell
Headquarters
Princeton
Website
Employees (FY)
517
Founded
2002
ISIN
US03152W1099
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of FOLD is 208.80 MXN — it has decreased by 10.39% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange AMICUS THERAPEUTICS INC stocks are traded under the ticker FOLD.
AMICUS THERAPEUTICS INC is going to release the next earnings report on May 7, 2024. Keep track of upcoming events with our Earnings Calendar.
FOLD stock is 11.59% volatile and has beta coefficient of 1.62. Check out the list of the most volatile stocks — is AMICUS THERAPEUTICS INC there?
One year price forecast for AMICUS THERAPEUTICS INC has a max estimate of 361.78 MXN and a min estimate of 230.23 MXN.
FOLD earnings for the last quarter are −1.22 MXN per share, whereas the estimation was −1.32 MXN resulting in a 7.76% surprise. The estimated earnings for the next quarter are −0.98 MXN per share. See more details about AMICUS THERAPEUTICS INC earnings.
AMICUS THERAPEUTICS INC revenue for the last quarter amounts to 1.80 B MXN despite the estimated figure of 1.78 B MXN. In the next quarter revenue is expected to reach 1.94 B MXN.
Yes, you can track AMICUS THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
FOLD net income for the last quarter is −574.83 M MXN, while the quarter before that showed −376.10 M MXN of net income which accounts for −52.84% change. Track more AMICUS THERAPEUTICS INC financial stats to get the full picture.
Today AMICUS THERAPEUTICS INC has the market capitalization of 52.11 B, it has decreased by 5.86% over the last week.
No, FOLD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, FOLD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AMICUS THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 20, 2024, the company has 517.00 employees. See our rating of the largest employees — is AMICUS THERAPEUTICS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AMICUS THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AMICUS THERAPEUTICS INC stock shows the sell signal. See more of AMICUS THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on AMICUS THERAPEUTICS INC future price: according to them, FOLD price has a max estimate of 361.78 MXN and a min estimate of 230.23 MXN. Read a more detailed AMICUS THERAPEUTICS INC forecast: see what analysts think of AMICUS THERAPEUTICS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AMICUS THERAPEUTICS INC EBITDA is −1.11 B MXN, and current EBITDA margin is −16.43%. See more stats in AMICUS THERAPEUTICS INC financial statements.